Newron Pharmaceuticals S.p.A. Return on Equity

Newron Pharmaceuticals S.p.A. (NP5.DE) currently reports a ROE of 35.45%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Newron Pharmaceuticals S.p.A.'s ROE history and peer comparisons.

Newron Pharmaceuticals S.p.A.'s ROE of 35.45% is higher than the Healthcare sector average of -75.84%. That is roughly 146.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Newron Pharmaceuticals S.p.A.'s current 35.45% should be judged against Healthcare norms (sector average: -75.84%) and against NP5.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 35.45%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Newron Pharmaceuticals S.p.A., and consider following NP5.DE for alerts when major investors trade the stock.

Newron Pharmaceuticals S.p.A. is classified in the Healthcare sector. On ROE, it currently shows 35.45% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NP5.DE with unrelated industries.